In eight phase 2 and phase 3 trials that were eligible for the pooled analysis (1,879 FH patients) [25–29], the clinical adverse events with PCSK9 antibody treatment mainly concerned headache, injection-site reactions, nasopharyngitis, gastroenteritis, nausea, and upper respiratory tract infections. Here, PCSK9 is linked to gastroenteritis.